Alprazolam
Title: Alprazolam
CAS Registry Number: 28981-97-7
CAS Name: 8-Chloro-1-methyl-6-phenyl-4H-[1,2,4]triazolo[4,3-a][1,4]benzodiazepine
Additional Names: 8-chloro-1-methyl-6-phenyl-4H-s-triazolo[4,3-a][1,4]benzodiazepine
Manufacturers' Codes: D-65MT; U-31889
Trademarks: Alplax (Gador); Cassadan (Temmler); Esparon (Orion); Tafil (Pharmacia); Tranquinal (Bago); Trankimazin (Pharmacia); Xanax (Pharmacia & Upjohn)
Molecular Formula: C17H13ClN4
Molecular Weight: 308.76
Percent Composition: C 66.13%, H 4.24%, Cl 11.48%, N 18.15%
Literature References: Prepn: J. B. Hester, DE 2012190; idem, US 3987052 (1970, 1976 both to Upjohn); J. B. Hester et al., Tetrahedron Lett. 1971, 1609; A. Walser, G. Zenchoff, J. Med. Chem. 20, 1694 (1977). Central depressant activity: R. Nakajima et al., Jpn. J. Pharmacol. 21, 497 (1971). Pharmacology: V. H. Sethy, Arch. Pharmacol. 301, 157 (1978). Clinical studies: L. F. Fabre, Curr. Ther. Res. 19, 661 (1976); J. B. Cohn, J. Clin. Psychiatry 42, 347 (1981). Pharmacokinetics: D. R. Abernethy et al., ibid. 44, 45 (1983). Review of pharmacokinetics, clinical efficacy, and mechanism of action: J. A. Fawcett, H. M. Kravitz, Pharmacotherapy 2, 242-254 (1982); of pharmacology and efficacy in anxiety and depression: Drugs 27, 132 (1984).
Properties: Crystals from ethyl acetate, mp 228-228.5°. Sol in alc. Insol in water. uv max (ethanol): 222 nm (e 40250). LD50 in mice, rats (mg/kg): 1020, >2000 orally; 540, 610 i.p. (Nakajima).
Melting point: mp 228-228.5°
Absorption maximum: uv max (ethanol): 222 nm (e 40250)
Toxicity data: LD50 in mice, rats (mg/kg): 1020, >2000 orally; 540, 610 i.p. (Nakajima)
NOTE: This is a controlled substance (depressant): 21 CFR, 1308.14.
Therap-Cat: Anxiolytic.
Keywords: Anxiolytic; Benzodiazepine Derivatives.

Others monographs:
NegamycinPyridinium Bromide Perbromide2,4-DinitrophenolCarindacillin
CapryleneMagnesium Silicideβ-ChloropropionitrileHexylcaine Hydrochloride
2-BromonaphthaleneSilicon TetrachloridePyroxylinZingerone
Dalfopristin1-OctanolHirudinBerberis Aristata
©2016 DrugLead US FDA&EMEA